According to a study published in the Journal of the American Society of Nephrology [1], empagliflozin, also known as Jardiance, has been shown to slow the decline of kidney function in patients with chronic kidney disease (CKD) [2]. Jardiance is a medication that belongs to the class of sodium-glucose cotransporter 2 (SGLT2) inhibitors, which work by preventing the kidneys from reabsorbing glucose back into the bloodstream [3].
Research has demonstrated that SGLT2 inhibitors like Jardiance can have a protective effect on kidney function, particularly in patients with diabetes. A study published in the New England Journal of Medicine [4] found that empagliflozin reduced the risk of kidney disease progression in patients with type 2 diabetes and established kidney disease.
DrugPatentWatch.com [5], a website that provides information on pharmaceutical patents, notes that Jardiance's patent has expired, making it a generic option available to patients. However, the exact formulation and dosing regimen of Jardiance may vary depending on the manufacturer and location.
It is essential to note that while Jardiance may have a positive effect on kidney function, it is essential for patients to consult with their healthcare provider to determine the best treatment plan for their individual needs.
Sources:
[1] https://jasn.asnjournals.org/content/31/1/101
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7145115/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7311915/
[4] https://www.nejm.org/doi/full/10.1056/NEJMoa1511925
[5] https://drugpatentwatch.com/drugs/empagliflozin